Congo's Ministry of Health reported 37 new deaths in a single 24-hour window spanning Friday, July 18, into Saturday, July 19, 2026, one of the highest single-day death tallies recorded since the Bundibugyo Ebola outbreak was declared on May 15, according to NPR and Al Jazeera. Those 37 deaths brought the cumulative confirmed toll to 930, from 2,344 laboratory-confirmed cases as of data through July 18, 2026.
The spike in daily deaths arrives at a moment when three first-ever clinical trials targeting the Bundibugyo strain specifically have just begun enrolling patients. The convergence of record-level daily deaths and first-ever treatment trials creates the most consequential week yet in a crisis that the World Health Organization has characterized as the fastest-growing Ebola outbreak in recorded history.
Why This Matters
A single-day death toll of 37 is not simply a statistical milestone. It reflects the pace at which Bundibugyo virus disease is consuming the response capacity of a region already overwhelmed by armed conflict, healthcare worker strikes, and supply shortages. Each of those deaths represents a person who was identified and confirmed as infected: they were known to the surveillance system, they were in the count, and still the outbreak killed them within a 24-hour window faster than the response could slow.
For the Bundibugyo virus specifically, there are no approved treatments and no approved vaccines. Every one of the 930 confirmed deaths has occurred without the benefit of a therapy proven in human patients to reduce mortality. That may change this week, as experimental drugs begin moving from laboratory evidence into controlled human trials. The clinical question is whether any trial data will mature quickly enough to influence the outbreak's current trajectory.
What We Know So Far
The 37 deaths in 24 hours were recorded across the outbreak's primary impact zones in Ituri Province and North Kivu, DRC's most severely affected provinces. Ituri Province alone accounts for 2,090 of the 2,344 confirmed cases, with 776 deaths in 27 of 36 health zones, according to the NICD and ECDC.
The response has faced compounding crises. At least 12 direct attacks on medical facilities and healthcare teams have occurred since mid-May. Healthcare workers have gone on strike to protest months of unpaid wages, and at least 36 healthcare workers have died of Bundibugyo infection. The WHO has explicitly noted that most cases are arising from unknown transmission chains, meaning contact tracing has not kept pace with the virus's spread.
Three first-ever clinical trials specifically targeting Bundibugyo ebolavirus are now enrolling patients in DRC, according to TechTimes. These include a trial of remdesivir, the broad-spectrum antiviral already used in some viral disease contexts; a trial of MBP134, a bispecific monoclonal antibody developed by Mapp Biopharmaceutical that has shown cross-reactive activity against Bundibugyo in laboratory studies; and the BD-Ebov Phase 1 vaccine trial from the University of Oxford.
Why These Trials Are Significant
All prior large-scale Ebola outbreak responses have had one tool that this response lacks: Ervebo, the Zaire-strain Ebola vaccine. In the 2018-2020 DRC outbreak, which killed more than 2,200 people over nearly two years, Ervebo was deployed and contributed meaningfully to outbreak containment by protecting healthcare workers and close contacts. But Ervebo's protective mechanism is calibrated to the Zaire strain's surface proteins, and Bundibugyo's surface proteins differ substantially. The WHO reviewed available evidence and formally recommended against using Ervebo for Bundibugyo patients outside controlled research settings.
The same limitation applies to ZMapp, REGN-EB3, and other monoclonal antibody cocktails approved for Zaire-strain Ebola. None were designed to target Bundibugyo's surface proteins, and cross-protection cannot be assumed.
This means the outbreak is running on supportive care alone: intravenous fluids, electrolyte management, oxygen, and treatment of secondary infections. Supportive care improved outcomes significantly in the 2018-2020 response, but without a targeted therapeutic, the case fatality rate remains high at approximately 39.7%.
What Doctors and Experts Say
The WHO's characterization of this as the fastest-growing Ebola outbreak on record reflects not only the raw case velocity but also the structural features that are driving it: a virus species for which the usual toolbox does not apply, operating in a conflict zone, against a health system stressed by strikes and attacks. Clinical trial data from remdesivir and MBP134 may provide the first evidence-based signal about whether either drug reduces mortality in Bundibugyo patients, but trials require weeks to months to generate meaningful data, and even approved drugs must then be manufactured and deployed at scale in a conflict zone.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Single-day death count: 37 new deaths in 24 hours (Friday July 18 to Saturday July 19, 2026), one of the highest daily tolls since outbreak declaration
- Cumulative deaths (July 18 data, reported July 20): 930
- Total confirmed cases: 2,344
- Case fatality rate: Approximately 39.7% (Africa CDC)
- WHO status: Public Health Emergency of International Concern (PHEIC), declared May 17, 2026
- Licensed vaccine for Bundibugyo: None
- Licensed treatment for Bundibugyo: None
- Clinical trials underway: Remdesivir; MBP134 (bispecific monoclonal antibody); BD-Ebov vaccine (Phase 1)
- Healthcare workers killed: At least 36
- What it shows: The outbreak remains in active, uncontrolled transmission despite response efforts, and the 37-death single-day figure confirms no sustained decrease in transmission
- What it does not show: Whether any of the clinical trials will produce a signal that changes the treatment landscape quickly enough to affect the current curve
- What readers should know: For the vast majority of Americans, direct risk remains very low. For Americans traveling to or working in DRC or Uganda, CDC Level 2 precautions apply.
Who Faces the Greatest Risk?
The risk profile for Americans remains the same as in prior MedicalDaily Ebola coverage:
- Humanitarian workers, journalists, and aid organization staff in DRC and Uganda face meaningfully elevated risk
- Two U.S. citizens have already been medically evacuated after confirmed Bundibugyo infection
- Anyone traveling to DRC should review the CDC Level 2 travel notice and have an evacuation plan in place before departure
- For the overwhelming majority of Americans with no planned travel to DRC or Uganda, direct exposure risk is very low
What You Can Do Now
- Americans traveling to DRC or Uganda should consult the CDC travel health notice for DRC and the Level 1 notice for Uganda before departure.
- Humanitarian organizations deploying staff should ensure all personnel have symptom reporting protocols, clear evacuation routes, and medical liaison support.
- Returnees from DRC or Uganda should self-monitor for 21 days per CDC guidance.
- Returning travelers who develop fever within 21 days of return should call ahead before visiting any health facility and disclose their travel history.
- Follow daily situation updates from the WHO , the ECDC , and the CDC Ebola situation summary .
What Happens Next
Clinical trial enrollment for remdesivir and MBP134 is underway. Early Phase 1/2 safety data will accumulate over weeks to months. If either drug shows a clear mortality-reduction signal, emergency authorization and rapid scale-up in the field would be the next steps. The WHO Emergency Committee is expected to reconvene to assess the PHEIC designation. Contact tracing coverage is at 85.8% for the primary provinces; reaching the remaining uncovered contacts is the outbreak response's most urgent operational priority. MedicalDaily will continue to report daily death toll updates and clinical trial announcements as they emerge.
The Bottom Line
37 new Bundibugyo Ebola deaths in a single 24-hour window confirm that DRC's outbreak remains in active, uncontrolled transmission even as three first-ever clinical trials targeting this specific virus strain have just begun enrolling patients. With no approved vaccine, no approved treatment, and a response hampered by armed conflict, healthcare worker strikes, and repeated attacks on medical facilities, the outbreak continues to grow at a pace the WHO has called the fastest in Ebola history. For Americans, direct risk remains very low. For the people of eastern DRC, the clinical trial results now underway may represent the first real opportunity to change the outbreak's trajectory.
